On Friday, Exelixis got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 90.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an 80 or better RS Rating at the beginning of a new price run.
See How IBD Helps You Make More Money In Stocks
Exelixis is not currently showing a potential entry point, having 5 consecutive up days, although on lower volume. See if the stock goes on to build a sound pattern with increased volume that could launch a new move. One to add to your watchlist.
While revenue growth fell last quarter from 67% to 32%, EPS grew 189%, up from 150% in the prior report.
The company holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals, Amphastar Pharmaceutcls and Harmony Biosciences are among the top 5 highly rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
